Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients

Autor: Marie Lundholm, Camilla Thellenberg-Karlsson, Thomas Wurdinger, Pernilla Wikström, Lee-Ann Tjon-Kon-Fat, Anders Widmark, Rolf Jonas Nilsson, Mona Schröder

Publikováno v: Prostate, 78(1), 48-53. Wiley-Liss Inc.
Tjon-Kon-Fat, L-A, Lundholm, M, Schröder, M, Wurdinger, T, Thellenberg-Karlsson, C, Widmark, A, Wikström, P & Nilsson, R J A 2018, ' Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients ', Prostate, vol. 78, no. 1, pp. 48-53 . https://doi.org/10.1002/pros.23443

Background: Novel therapies for castration resistant prostate cancer (CRPC) have been introduced in the clinic with possibilities for individualized treatment plans. Best practice of those expensive drugs requires predictive biomarker monitoring. Thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::153c39abe2cb97f81c75ccb69f01e41f
https://research.vumc.nl/en/publications/567e6983-365a-432b-abaa-46c44a3ddea0